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Abstract
Daily injections of insulin provide lifesaving benefits to millions of diabetics. But currently 
available prandial insulins are suboptimal: The onset of action is delayed by slow dissociation of 
the insulin hexamer in the subcutaneous space, and insulin forms amyloid fibrils upon storage in 
solution. Here we show, through the use of non-canonical amino acid mutagenesis, that 
replacement of the proline residue at position 28 of the insulin B-chain (ProB28) by (4S)-
hydroxyproline (Hzp) yields an active form of insulin that dissociates more rapidly, and fibrillates 
more slowly, than the wild-type protein. Crystal structures of dimeric and hexameric insulin 
preparations suggest that a hydrogen bond between the hydroxyl group of Hzp and a backbone 
amide carbonyl positioned across the dimer interface may be responsible for the altered behavior. 
The effects of hydroxylation are stereospecific; replacement of ProB28 by (4R)-hydroxyproline 
(Hyp) causes little change in the rates of fibrillation and hexamer disassociation. These results 
demonstrate a new approach that fuses the concepts of medicinal chemistry and protein design, 
and paves the way to further engineering of insulin and other therapeutic proteins.
Blood glucose levels are tightly controlled in mammals through a sensitive regulatory 
system mediated by insulin, a 51-amino acid endocrine hormone composed of two disulfide-
linked polypeptide chains (designated A and B). Upon binding to its receptor, insulin 
initiates a signaling cascade that accelerates glucose uptake and glycogen production. In 
diabetic patients, this system malfunctions, and glucose levels must be controlled through 
subcutaneous injections of insulin1. The C-terminus of the B-chain is important in mediating 
dimerization of the hormone2–3, and the flexibility of the B-chain C-terminus is believed to 
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contribute to aggregation through formation of amyloid fibrils4–6. Pharmaceutical 
formulations of insulin are stabilized with respect to fibrillation by addition of zinc and 
phenolic preservatives, which drive assembly of the R6 hexamer (Fig. 1a)7–9. The R6 form of 
insulin is inactive and dissociates slowly to its active monomeric form after subcutaneous 
injection; the lag time for dissociation delays the onset of action10. Mutation of ProB28 
yields rapid-acting insulins (RAIs) by disrupting contacts that are critical for dimer 
formation8, but replacement of Pro through conventional mutagenesis also increases the 
flexibility and perturbs the trajectory of the protein backbone (Fig. 1B). We sought a means 
to disrupt the dimer interface without releasing the conformational constraints characteristic 
of proline by using non-canonical amino acid (ncAA) mutagenesis11–13. Specifically, we 
introduced hydroxyl groups at the 4-position of ProB28 (Fig. 1B, C) by replacing Pro with 
Hzp or Hyp. In addition to introducing a polar functional group and the capacity for 
hydrogen-bonding (including transannular hydrogen bonding), hydroxylation at the 4-
position is known to alter the endo/exo preference of the pyrrolidine ring and the cis/trans 
equilibrium of the backbone amide bond14–16.
We expressed modified proinsulins (PIs) in the proline-auxotrophic E. coli strain CAG18515 
in M9 minimal media supplemented with Hyp or Hzp. The extent of replacement of Pro by 
either Hyp or Hzp was approximately 90%17–18 as determined by matrix-assisted laser 
desorption/ionization mass spectrometry (MALDI-MS; fig. S1). Denatured PIs were purified 
by Ni-NTA affinity chromatography in yields of 32 mg/L for Hzp-PI and 29 mg/L for Hyp-
PI (table S1) from the inclusion body fraction. The PIs were refolded and cleaved with 
trypsin and carboxypeptidase B19. The resulting mature insulins were purified by reversed 
phase HPLC18–19, and proper proteolytic processing of each variant was verified by 
MALDI-MS (table S1). Wild-type insulin (ProI) and RAI Aspart (AspI, in which ProB28 is 
replaced by aspartic acid) were produced similarly. All of the variants caused similar 
reductions in blood glucose upon subcutaneous injection into diabetic mice (Fig. 1D)2, 20–22. 
RAIs cannot be distinguished from ProI in rodent models23.
In the absence of Zn2+ and phenolic preservatives, insulins dimerize with a dissociation 
constant (KD) of approximately 10 µM. In contrast, KD for RAIs is typically >500 µM, and 
it is believed that destabilization of the dimer interface causes the accelerated onset of 
insulin action after subcutaneous injection20, 24–25. Monomeric forms of insulin give rise to 
characteristic circular dichroism (CD) spectra with distinct minima at 208 and 222 nm26–27 
(e.g., AspI; Fig. 2A). Dimerization causes a loss of negative ellipticity at 208 nm27 (e.g., 
ProI; Fig. 2A). At a concentration of 60 µM, Hypl appears to be monomeric (with a CD 
spectrum nearly identical to that of AspI; Fig. 2A) while the spectrum of HzpI suggests a 
dimeric insulin (Fig. 2A). Sedimentation velocity (SV) and sedimentation equilibrium (SE) 
experiments were consistent with the results of the CD analysis (fig. S3). SE data were fitted 
to a model of monomer-dimer-hexamer self-association (SEDPHAT) 28–29, and yielded 
monomer-dimer dissociation constants (KD) of >200 µM and 25 µM for HypI and HzpI, 
respectively.
Previous studies of RAIs have shown that destabilization of the dimer interface correlates 
with accelerated dissociation of the hexamer and rapid onset of insulin action8, 13. Triggered 
dissociation of Zn2+-hexamers by addition of terpyridine30 revealed nearly identical rates of 
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dissociation for HypI and ProI, (τ1/2 = 87.0 ± 10 s and 90.4 ± 4.2 s, respectively; Fig. 2B and 
fig. S4) while HzpI exhibited kinetics similar to those of AspI (τ1/2 = 53.6 ± 3.7 s and 42.7 
± 4.3 s, respectively; Fig. 2B and fig. S4). We found these results surprising – replacement 
of Pro by Hyp destabilizes the dimer but has essentially no effect on hexamer dissociation, 
while introduction of Hzp causes little change in dimer stability but a substantial increase in 
the rate of hexamer disassembly.
Each of the insulin variants was subjected to fibrillation lag time analysis (Fig. 2C)31. We 
found similar times to onset of fibrillation for HypI, ProI and AspI; in contrast, HzpI is 
markedly more resistant to aggregation, with a mean time to onset more than three-fold 
longer than that observed for ProI. The behavior of HzpI is especially striking, in that it 
combines fast hexamer dissociation with enhanced stability toward fibrillation.
Each subunit in the insulin hexamer adopts one of two conformational states (T or R), 
depending on the concentration of phenolic ligand (Fig. 1A)13. Pharmaceutical formulations 
are prepared in the more stable R6 form, whereas the T-state is observed in the absence of 
phenolic ligands, most commonly in the form of T2-dimers32. To elucidate the molecular 
origins of the dissociation and fibrillation behavior of HypI and HzpI, we examined crystal 
structures of both states.
Hydroxylation at ProB28 does not cause substantial perturbation of the overall insulin 
structure (Fig. 3, fig. S5). In comparison with ProI, the backbone RMSD values of HypI and 
HzpI are 0.31 Å (T2- HypI), 0.44 Å (T2- HypI), 0.38 Å (R6- HypI) and 0.69 Å (R6- HypI)33. 
The most notable feature of the HzpI structures is the proximity of the hydroxyl group of 
Hzp to the backbone carbonyl oxygen atom of GluB21′, which lies across the dimer 
interface (denoted by prime; Fig. 3B, E). The inter-oxygen distances (2.8 Å in the T2 
structure, 2.7 Å in R6), are consistent with the formation of strong hydrogen bonds between 
the hydroxyl group of HzpB28 and the backbone carbonyl of GluB21′ in both structures. 
An analogous hydrogen bond has been observed in a structure (PDB ID: 1ZEH) of R6-AspI 
co-crystallized with m-cresol34; here the phenolic ligand serves as the hydrogen-bond donor 
(fig. S6). Although the significance of this hydrogen bond has not been discussed in the 
literature, we suggest that it may play an important role in determining the relative stabilities 
of the insulin species involved in dissociation and fibrillation. In contrast to the (4S)-
hydroxyl group of Hzp, the (4R)-hydroxyl of HypB28 does not contact any 
crystallographically resolved hydrogen bond acceptor in the T2-structure (Fig. 3C), and 
appears to bond to an ordered water molecule in the R6-hexamer (Fig. 3F). The absence of 
new hydrogen-bonding interactions is consistent with the unaltered dissociation and 
fibrillation kinetics of HypI.
Taken together, our results show that replacement of Pro by Hzp at position 28 of the insulin 
B-chain introduces a new hydrogen bond across the inter-subunit interface, accelerates 
hexamer dissociation and delays the onset of fibrillation (Table 1). We suggest that the 
hydrogen bond between Hzp and Glu21′ may stabilize the dimer relative to the hexamer, or 
perhaps reduce the energy of the transition state for the conformational change from the R-
state to T-state, and thereby speed disassembly. The delayed onset of fibrillation may reflect 
changes in the structure and dynamics of the HzpI monomer or in the kinetics of fibril 
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nucleation. Subtle conformational effects caused by 4S-substitution on the pyrrolidine ring 
may also contribute to the observed behavior.35 Whether or not these hypotheses are correct, 
the results described here demonstrate the power of ncAA mutagenesis to control 
functionally relevant biophysical properties of therapeutic proteins. We anticipate that this 
approach will find increasing application in the design of antibody-drug conjugates, 
bispecific antibodies, and other novel protein therapeutics.
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Hzp (4S)-hydroxyproline
Hyp (4R)-hydroxyproline
RAI Rapid Acting Insulin
ncAA non-canonical amino acid
PI proinsulin
HypI Hyp-Insulin
HzpI Hzp-Insulin
ProI Wild-type human insulin
AspI Insulin Aspart
CD circular dichroism
SV sedimentation velocity
SE sedimentation equilibrium
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Figure. 1. Hydroxyinsulins retain activity
(A) Schematic of hexamer disassembly (adapted from mechanism previously described 8). 
Phenolic ligand (Ph), zinc ion (Zn2+), insulin monomer (triangle). Darker shading indicates 
the R-state of the hexamer. (B) Structures of the B-chain C-termini of wild-type insulin 
(ProI) and RAI Aspart (AspI). (C) Chemical structures of L-proline (1), (2S,4S)-
hydroxyproline (Hzp; 2), (2S,4R)-hydroxyproline (Hyp; 3). (D) Reduction of blood glucose 
following subcutaneous injection of 35 µg/kg insulins into streptozotocin-induced diabetic 
mice. Glucose levels were measured post-injection via tail vein sampling. ProI, AspI, HzpI, 
HypI or vector were formulated as described 22. Error bars denote one standard deviation (n 
= 3).
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Figure. 2. Hydroxylation at ProB28 modulates insulin dimerization, dissociation kinetics, and 
stability
(A) Far UV CD spectra collected on 60 µM insulins in 10 mM phosphate buffer, pH 8.0 at 
25°C. (B) Insulin hexamer dissociation following sequestration of Zn2+ by terpyridine. 
Zn2+-(terpy) signal was monitored at 334 nm and fitted to a mono-exponential decay. HzpI 
and HypI contain 10% ProI. The curves for HypI and ProI are indistinguishable in this plot. 
(C) Representative fibrillation curves for 60 µM insulins (37°C, 960 RPM; n=4). Insulin 
fibrils were detected by the rise in Thioflavin T (ThT) fluorescence that accompanies 
binding to fibrillar aggregates.
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Figure. 3. Crystal structures of HzpI and HypI
In tan (left), wt insulins from PDB (3T2A, 1ZNJ) highlighting the distance between the 
carbon atom at the 4th position of ProB28 and its closest neighbors, backbone carbonyl 
oxygen atoms of GlyB20’ and GluB21 in the T2 dimer (A) and R6 hexamer (D) forms. In 
grey (middle), HzpI in the T2 dimer (B) and R6 hexamer (E) forms. In blue (right), HypI in 
the T2 dimer (C) and R6 hexamer (F) forms.
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Table 1
Biophysical Characteristics of Insulin Variants
Protein Hexamer t½ (s) Fibrillation lag time(h) KD dimer (μM)
Prol 90.4 ± 4.2 5.1 ± 1.5 9 μM
Hzpl* 53.6 ± 3.7 19.6 ± 2.6 ~25 μM
Hypl* 87.0 ± 10 5.5 ± 1.2 >200 μM
Aspl 42.7 ± 4.3 5.3 ± 1.0 >500 μM
Errors are given as one standard deviation (n > 4).
*10% Prol present.
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